Cargando…

Experimental and modeling of solubility of sitagliptin phosphate, in supercritical carbon dioxide: proposing a new association model

The solubility of an anti-hyperglycemic agent drug, (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4] triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine (also known as Sitagliptin phosphate) in supercritical carbon dioxide (scCO(2)) was determined by ananalytical and dynami...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardestani, Nedasadat Saadati, Sajadian, Seyed Ali, Esfandiari, Nadia, Rojas, Adrián, Garlapati, Chandrasekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579220/
https://www.ncbi.nlm.nih.gov/pubmed/37845347
http://dx.doi.org/10.1038/s41598-023-44787-z
Descripción
Sumario:The solubility of an anti-hyperglycemic agent drug, (R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4] triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl) butan-2-amine (also known as Sitagliptin phosphate) in supercritical carbon dioxide (scCO(2)) was determined by ananalytical and dynamic technique at different temperatures (308, 318, 328 and 338 K) and pressure (12–30 MPa) values. The measured solubilities were in the range of 3.02 × 10(–5) to 5.17 × 10(–5), 2.71 × 10(–5) to 5.83 × 10(–5), 2.39 × 10(–5) to 6.51 × 10(–5) and 2.07 × 10(–5) to 6.98 × 10(−5) in mole fraction at (308, 318, 328 and 338) K, respectively. The solubility data were correlated with existing density models and with a new association model.